Product category:
Contract research
News Release from: Argenta Discovery
Edited by the Laboratorytalk Editorial
Team on 16 December 2005
Two year drug discovery agreement with
Genentech
Argenta Discovery, a contract drug discovery and respiratory drug development company, has entered into a two-year drug discovery collaboration with Genentech
Scientists from the two companies will exploit Argenta's expertise in computer-aided drug design (Cadd), medicinal chemistry, biology and Adme/PK to discover new chemical entities acting against an undisclosed drug target defined by Genentech Commenting on the agreement, Christopher Ashton, Argenta's CEO, said, "We are delighted that Genentech has chosen to work with Argenta on this important programme
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
"This is our first collaboration with the company and we believe its decision to work with Argenta is a tribute to the skills of our 90-strong drug discovery team.
"It is gratifying that Argenta's determination to refine and broaden its integrated drug discovery capabilities should be rewarded with high calibre collaborations of this kind.
"Our objective is to secure and retain more high quality, long-term collaborations with leading pharmaceutical and biotechnology companies and today's announcement is another step towards realising that objective.
"We look forward to building a long and successful relationship with Genentech.".
• Argenta Discovery: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
